Copyright
©The Author(s) 2020.
World J Gastroenterol. Apr 21, 2020; 26(15): 1745-1757
Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1745
Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1745
Figure 1 The expression of DNAH17-AS1 is upregulated in pancreatic carcinoma patients.
A: Volcano plot of the TCGA_lncRNA profile. The top ten highly expressed lncRNAs are marked in green; B: The expression pattern of DNAH17-AS1 in pancreatic carcinoma (PC) patients and normal patients from The Cancer Genome Atlas dataset; C: DNAH17-AS1 expression in PC tissues collected by our hospital; D: DNAH17-AS1 expression in Hs766T, SW1990, and HPDE6-C7 cells; E: Dysregulation of DNAH17-AS1 is related to overall survival in PC patients; F: Dysregulation of DNAH17-AS1 is related to disease-free survival in PC patients. bP < 0.01. DFS: Disease-free survival; OS: Overall survival.
- Citation: Xu T, Lei T, Li SQ, Mai EH, Ding FH, Niu B. DNAH17-AS1 promotes pancreatic carcinoma by increasing PPME1 expression via inhibition of miR-432-5p. World J Gastroenterol 2020; 26(15): 1745-1757
- URL: https://www.wjgnet.com/1007-9327/full/v26/i15/1745.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i15.1745